- Alfuzosin
drugbox
IUPAC_name = "N"- [3- [(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino] propyl] tetrahydrofuran- 2-carboxamide
CAS_number = 81403-80-7
ATC_prefix = G04
ATC_suffix = CA01
PubChem = 2092
ChemSpiderID = 2008
DrugBank = APRD00490
C = 19 | H = 27 | N = 5 | O = 4
molecular_weight = 389.449 g/mol
bioavailability = 49%
protein_bound = 82%-90%
metabolism = Hepatic (CYP3A4 -mediated)
elimination_half-life = 10 hours
excretion = Fecal (69%) and renal (24%)
pregnancy_AU = B2
pregnancy_US = B
legal_UK = POM
legal_US = Rx-only
routes_of_administration = OralAlfuzosin (INN, provided as the
hydrochloride salt) is an α1 receptor antagonist used to treatbenign prostatic hyperplasia (BPH). It works by relaxing the muscles in theprostate and bladder neck, making it easier to urinate.Alfuzosin is marketed in the
United States bySanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xatral. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.Side effects
The most common side effects are
dizziness (due topostural hypotension ),upper respiratory tract infection ,headache , and fatigue.Contraindications
Alfuzosin should be used with caution in
patient s with severerenal insufficiency , and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong theQT interval .External links
* [http://www.uroxatral.com/ Uroxatral] (manufacturer's website)
* [http://www.meds-help.com/alfuzosin/ Alfuzosin] (patient information)
Wikimedia Foundation. 2010.